Skip header and navigation

3 records – page 1 of 1.

Document Type
Rapid Review
Review Code
PPE120901 RR
Question Submitted
December 9, 2020
Date Completed
December 18, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Document Type
Rapid Review
Review Code
PPE120901 RR
Question Submitted
December 9, 2020
Date Completed
December 18, 2020
Status
3. Completed
Research Team
Personal Protective Equipment
Key Findings
Moderate evidence supporting the concept that airway management and certain surgical procedures create aerosols
No definitive evidence for the transmission of SARS-CoV-2 during AGMP
Indirect evidence from SARS-CoV-1 indicates that HCW present during AGMP are at higher risk of infection, but evidence quality is very low and very difficult to generalize
The absence of definitive evidence does not equate to the absence of risk and most policy recommendations err on the side of safety for Health Care Workers
Category
Infection Prevention and Control
Subject
Aerosols
Risk
Transmission
Population
All
Clinical Setting
Ambulatory
Long Term Care
Priority Level
Level 2 One week (7 days)
Cite As
Badea, A; Groot, G; Fox, L; Mueller, M. What is the risk of COVID-19 transmission during AGMP procedures? 2020 Dec 18; Document no.: PPE120901 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 30 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EOC040101 RR
Question Submitted
April 1, 2020
Date Completed
April 1, 2020
Status
3. Completed
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC040101 RR
Question Submitted
April 1, 2020
Date Completed
April 1, 2020
Status
3. Completed
Research Team
EOC
Key Findings
· There are some recommendations and precautions from WHO, CDC, Canada and the UK that there is transmission of the COVID virus from the administration of nebulizer medication. · Some case studies of SARS found few instances that patients may likely be infected after aerosol generating procedures including nebulized medications, and although there are few evidences that demonstrates low risk of viral transmission from nebulizers, possibility of transmission remains
Category
Epidemiology
Infection Prevention and Control
Subject
Aerosols
Risk
Transmission
Population
All
Clinical Setting
Ambulatory
Priority Level
Level 2 completed within 8 hours
Cite As
Badea, A; Groot, G; Fenton, M; Dalidowicz, M; Young, C. What is the degree of COVID-19 transmission through the administration of nebulizer medication either in clinical practice or in animal experiments? 2020 Apr 1; Document no.: EOC040101 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 10 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EOC033001 RR
Question Submitted
March 30, 2020
Date Completed
March 30, 2020
Status
3. Completed
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC033001 RR
Question Submitted
March 30, 2020
Date Completed
March 30, 2020
Status
3. Completed
Research Team
EOC
Key Findings
· Some countries like Taiwan and Malaysia have created their own intubation hood design as others offered to produce or modify the original design to fit their country’s equipment. · Several countries have also created innovation in airway management such as 3D printed respirator valves for hospitals and 3D printed ventilators. · An Emergency physician in Northern Italy shared that due to influx of patients in the hospitals, “intubation and invasive mechanical ventilators in the ED are reserved for patients not responsive to NIV” although in principle can give a more favorable chance for patients if given before their condition deteriorates.
Category
Infection Prevention and Control
Subject
Intubation
Aerosols
Population
All
Clinical Setting
Ambulatory
Cardiac unit
Priority Level
Level 2 completed within 8 hours
Cite As
Badea, A; Groot, G; Dalidowicz, M. Where and how are they producing and using intubation hoods? 2020 Mar 30; Document no.: EOC033001 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 7 p. (CEST rapid review report)
Similar Reviews
EOC090202 RR
Related Documents
Documents
Less detail